

FDA Approves Milnacipran for Fibromyalgia

BY ELIZABETH MEHCATIE
Senior Writer

Milnacipran, a selective serotonin and norepinephrine dual reuptake inhibitor, has been approved by the Food and Drug Administration for the management of fibromyalgia in adults, the third drug approved for this indication.

Approval was based on the results of

two phase III studies of a total of 2,084 patients with fibromyalgia, which found that during 3-6 months of treatment, those (1,460 patients) treated with 100 mg or 200 mg of milnacipran per day experienced statistically significant and clinically meaningful improvements in pain, patient global assessment, and physical function, compared with those on placebo.

A 30% or greater improvement in pain


scores at 15 weeks was reported by 56% of patients on the 200-mg dose and 53% on the 100-mg dose, both significantly better than the 41% on placebo.

Milnacipran is expected to be available in pharmacies in March, according to Forest Laboratories Inc. and Cypress Bioscience Inc., which will market it under the trade name Savella.

The FDA has determined that a Risk Evaluation and Mitigation Strategy

(REMS) plan is necessary for milnacipran “to ensure that the benefits of the drug outweighs the risks,” according to the FDA’s approval letter, which notes that the serious risks associated with drugs in this class are serious psychiatric symptoms, including suicidal ideation, particularly in patients with depression. The letter noted that patients with fibromyalgia often have other mood disorders, such as major depression. ■

COUGH MEDICINE THIS POWERFUL
SHOULD NEVER BE
CHUGGED, GULPED, OR SWIGGED.



Finally, accurate dosing for cough control is now available in a capsule.

Introducing TussiCaps,[®] up to 12 hours of cough relief in a capsule—so dosing is easier for your patients to get right every time. For more information visit capthecough.com.

TussiCaps is indicated for relief of cough and upper respiratory symptoms associated with allergy or colds in adults and children 6 years of age and older.

For more information about TussiCaps, please see Brief Summary on the following pages.

Important Safety Information:

TussiCaps is contraindicated in the presence of known allergy to hydrocodone or chlorpheniramine. TussiCaps is contraindicated in children under 6 years of age. The most common adverse reactions associated with TussiCaps are sedation, drowsiness, and mental clouding, which may impair the mental and/or physical abilities required for potentially hazardous tasks. As with other drugs in this class, the possibility of tolerance and/or dependence, particularly in patients with a history of drug dependence, should be considered.

capthecough.com

TussiCaps
Hydrocodone polistirex @
Chlorpheniramine polistirex
extended-release capsules 5/4 • 10 mg/8 mg

TussiCaps and M are registered trademarks of Mallinckrodt Inc. TussiCaps logo is a trademark of Mallinckrodt Inc. COVIDIEN and COVIDIEN with Logo are trademarks of Covidien AG. © 2008 Covidien. All rights reserved.

 **COVIDIEN**